证券日报网讯12月9日晚间，博济医药（300404）发布公告称，公司获得国家知识产权局颁发的发明专 利证书，发明名称为"一种双氯芬酸钠药物制剂及其制备方法和应用"，专利号ZL202510581633.4，授权 公告日2025年12月5日。公司表示，该专利有利于技术创新，完善知识产权保护体系，提升核心竞争 力。 ...

Core Insights - The single License-out transaction amount has surpassed $3 billion, and the total overseas transaction amount for the year is approaching $100 billion, indicating that Chinese innovative drugs have quietly entered the "hard currency" era [1][3] - This surge in transaction volume signals a systematic rise of the Chinese pharmaceutical industry within the global value chain, driven by qualitative changes in R&D capabilities and strategic vision [1][3] Industry Challenges - Key questions need to be clarified amidst the excitement: Is the explosion of transactions an偶然 or a必然? What are the deep drivers behind the $92.03 billion figure? [2][4] - How can leading companies transition from "selling rights" to "co-creating"? [2][4] - How can small and medium-sized pharmaceutical companies avoid the red ocean and find their own "small but beautiful" pathways for overseas expansion? [2][4] - In the face of valuation bubbles and negotiation games, how can companies scientifically grasp the timing of licensing and anchor fair prices? [2][4] Event Announcement - On December 17, a live session titled "New Drug Relativity" will be co-hosted by Yaoduo and Boji Pharmaceutical, addressing these core issues with industry experts [2][4][5] - The session will feature Wan Jin, founding partner of Yuanjin Venture Capital, James Li, Vice President of Business Development at BIOTrialMed, and Ding Hongxia, co-founder of Yaoduo, to explore the core dynamics and future directions of the globalization of Chinese innovative drug value [2][4][5] Company Overview - Yaoduo is a "drug research and development intelligent innovation service platform" driven by big data and deep intelligence interpretation [3][5] - Since its establishment, Yaoduo has focused on integrating advanced IT technologies such as big data, knowledge graphs, and artificial intelligence with pharmaceutical professional knowledge, building a robust pharmaceutical big data collection system [3][5] - With over 10 years of accumulation, Yaoduo possesses a vast data lake/warehouse (500TB) and has developed unique algorithms for deep trend prediction and opportunity recommendation, empowering decision-making and innovation in the pharmaceutical industry [3][5]

每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 王晓波） 每经AI快讯，博济医药（SZ 300404，收盘价：9.69元）12月8日晚间发布公告称，近日，博济医药科技 股份有限公司获得国家知识产权局颁发的一项发明专利证书。专利名称为"一种双氯芬酸钠药物制剂及 其制备方法和应用"。 2025年1至6月份，博济医药的营业收入构成为：服务业占比99.46%，其他业务占比0.54%。 截至发稿，博济医药市值为37亿元。 ...

| 序号 | 发明名称 | 专利权人 证书号 | 专利号 专利申请日 | | | 授权公告日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一种双氯芬酸钠 药物制剂及其制 | 博济医药科 技股份有限 第8550081号 | ZL 2025 1 | 年 2025 | 05 | 年 2025 12 | | | | | | 0581633.4 | 月 07 | 日 | 月 05 | 日 | | | 备方法和应用 | 公司 | | | | | | 本发明涉及药物制剂技术领域，提供了一种双氯芬酸钠药物制剂及其制备方 法和应用。本发明药物制剂中活性成分双氯芬酸钠通过脂质体递送给药，赋予了 制剂更好的透皮吸收效果；同时，还具有优异的控释效果，使得血药浓度更平稳， 且将其包封于脂质体微囊内，有效降低了对胃肠的刺激，可有效提高患者依从性。 该药物制剂不仅可以制成外用透皮贴剂，还可制成内服控释制剂，应用广泛。 二、对公司的影响 证券代码：300404 证券简称：博济医药 公告编号：2025-085 博济医药科技股份有限公司 关于公司获得发明专利证书的公告 ...

博济医药科技股份有限公司 简式权益变动报告书 上市公司名称：博济医药科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：博济医药 股票代码：300404 信息披露义务人（一）：王廷春 通讯地址：广东省广州市天河区*** 信息披露义务人（二）：赵伶俐 通讯地址：广东省广州市天河区*** 信息披露义务人（三）：横琴广金美好基金管理有限公司－广金美好费米十 三号私募证券投资基金 通讯地址：广东省广州市黄埔区归谷科技园 C4 栋 1302 股份变动性质：持股比例减少 签署日期：二〇二五年十二月三日 1 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司收购管理 办法》（以下简称"《收购办法》"）、《公开发行证券的公司信息披露内容与 格式准则第 15 号——权益变动报告书（2025 年修订）（以下简称"《准则第 15 号》"）等相关规定编制本报告书。 二、本信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《收购办法》《准则第 15 号》等规定，本报告书已全面 披露信息披露义务人在博济医 ...

证券代码：300404 证券简称：博济医药 公告编号：2025-084 博济医药科技股份有限公司 关于控股股东及其一致行动人减持股份触及 1%及 5%整数倍 暨简式权益变动报告书的提示性公告 公司控股股东王廷春先生及其一致行动人赵伶俐、横琴广金美好基金管理有 限公司－广金美好费米十三号私募证券投资基金保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 截至 2021 年 6 月 30 日，王廷春及其一致行动人赵伶俐合计持有公司股份 100,729,642 股，占公司当时总股本的比例为 38.55%。自 2021 年 6 月 30 日至 2025 年 12 月 3 日，信息披露义务人因一致行动人内部划转、股权激励计划、权益分 派、股份减持和向特定对象发行股票等原因导致其所持股数量及持股比例发生变 动。具体变动情况如下： 1、本次权益变动性质为持股比例减少，不触及要约收购，也不会导致公司 控股股东及实际控制人发生变化。 2、本次权益变动后，公司控股股东、实际控制人王廷春先生及其一致行动 人赵伶俐女士、横 ...

Core Viewpoint - The announcement from Boji Pharmaceutical indicates that major shareholders Wang Tingchun, Zhao Lingli, and Feimi No. 13 plan to reduce their holdings by 8.4258 million shares, representing 2.18% of the total share capital [1] Shareholding Changes - The combined shareholding of the three major shareholders decreased from 38.55% on June 30, 2021, to 35% as of December 3, 2025, which accounts for 35.24% of the total share capital after excluding shares in the repurchase account [1] - The equity change triggers thresholds of 1% and 5% [1] Control and Implementation - This reduction in shareholding will not result in a change of control for the company [1] - The share reduction plan has not yet been fully implemented [1]

博济医药公告，信息披露义务人王廷春、赵伶俐及横琴广金美好基金管理有限公司－广金美好费米十三 号私募证券投资基金因股权激励计划、权益分派、股份减持和向特定对象发行股票等原因，合计持股比 例从38.55%减少至35.00%。 ...

Group 1 - On December 3, 2025, Boji Pharmaceutical had a block trade of 3.867 million shares, with a transaction value of 31.7829 million yuan, accounting for 36.16% of the total transaction value for the day [1] - The average transaction price was 8.22 yuan, representing a discount of 15.62% compared to the market closing price of 9.74 yuan [1] - The highest transaction price recorded was 8.68 yuan, while the lowest was 7.94 yuan [1] Group 2 - Specific transactions on December 3, 2025, included a sale at 7.94 yuan for 30.91 million shares by Ping An Securities and a sale at 8.68 yuan for 145.79 million shares by Tianfeng Securities [2] - Other notable transactions involved sales at 7.94 yuan for 110 million shares by Guotai Junan Securities and 100 million shares by Tianfeng Securities [2]

Core Viewpoint - The company, Boji Pharmaceutical, has not yet developed its own drugs but is providing clinical research services for various treatments related to influenza and other acute respiratory infections, leveraging AI technology to enhance efficiency and quality [1] Group 1 - The company is currently not engaged in the independent development of related drugs [1] - Boji Pharmaceutical offers clinical research services targeting different patient populations for treatments of type A influenza, common influenza, and other acute upper respiratory infections [1] - The company is actively utilizing AI technology to improve the efficiency and quality of its services [1]